Business Wire

CA-UNVARNISHED

Share
The First of Five Architectural Masterpieces at The Case, Malibu’s Only New Guard Gate Community in Decades, Lists for $69.995 Million

After more than a decade in approvals, design, and construction, Scott Gillen, visionary home designer, creator and founder of Unvarnished , has listed for sale the first of five estates in the 24-acre private enclave known as The Case. The first guard gated community built in Malibu in decades, The Case comprises five spectacular mid-century modern inspired homes perched above The Colony on Malibu’s most coveted oceanfront bluff and represents the largest private residential development in its history. The Edge, on the market for $69.995 million , will be the first home completed within the community and will be delivered turnkey, providing the buyer instant gratification of unprecedented luxury and hand-crafted design perfection. All five bespoke homes are currently under construction, with the remaining homes slated for full completion throughout the year.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220615006048/en/

“The Case is my largest and most epic project to date. The opportunity to create a community of five homes on one of, if not the best bluff top on the California coast, was something I could not pass up. Frankly, ten minutes after I stepped on the property, I knew I would buy it,” said Scott Gillen, the founder of Unvarnished. “The sheer size of the property and the ability to build 10,000 to 12,000-square foot single story homes created immense challenges and unbelievable opportunities for me to take some of my foundational design principles--use of warm natural materials, a nod toward mid-century modern, large, opened spaces, lots of natural light and blurring the line between indoors and out-- which are also tenets of mid-century modern architecture--to the next level. So, it was natural that my designs for The Edge, and the other homes at The Case, take enormous inspiration from mid-century modern architecture, and then I incorporate construction techniques and furnishings, the quality of which are rarely, if ever, found in new development, to create a unique experience of luxury living on the coast of Malibu, a place unlike anywhere else in the world. I’m very proud of how The Edge has turned out and I’m incredibly excited to bring it to market.”

The 2.6-acre estate, providing cinematic views of the Queen’s necklace, Palos Verdes to Point Dume, embodies the essence of casual luxury living. Spanning approximately 10,500 square feet, the single-story home offers five ensuite bedrooms and three half baths, and includes a Bulthaup chef’s kitchen, expansive great room, a master bedroom with outdoor spa, and floor to ceiling glass doors that open to a 10,000-square foot Ipe deck with cabana and outdoor kitchen.

The Edge, named for its stunning nearly 80-foot double-sided infinity edge freshwater pool that juts out like a diving board into the Pacific Ocean, with famed Catalina Island in the distance, is architecturally inspired by the giants of mid-century modern, Lloyd Wright, Neutra, Lautner and Quincy Jones, to name but a few. The magnificent home also includes hand-picked custom furnishings by Minotti and Gillen, Miele and Gaggenau appliances, custom cabinets, a 650-bottle teak wine room, a glass and teak enclosed private library, and a home theatre that is a room “floating” inside another room to achieve the ultimate home cinema experience.

The Case is the crown jewel of Scott Gillen’s visionary Malibu Series, where each home is a sanctuary unto itself. Behind its 24-hour manned guard gate and security features designed by international renowned security expert Gavin de Becker, residents of The Case will live with ultimate peace of mind and privacy.

The Case comprises five distinct mid-century modern homes: The Cantilever House (Case Study No. 1), The Butterfly House (Case Study No. 2), The Edge (Case Study No. 3), The Flat House (Case Study No. 4) and The Glass Tunnel (Case Study No. 5).

For more information, visit www.unvarnishedco.com or contact listing agent Sandro Dazzan of The Agency.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye